Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
This work warrants further investigation of LNP-formulated mRNA vaccines for TB, whilst indicating the potential of m-Mix and C-m-Mix to progress to further stages of vaccine development.
Authors
- Elena Stylianou (ORCID: https://orcid.org/0000-0002-1384-9367)
- Christopher J. De Voss (ORCID: https://orcid.org/0000-0002-6454-0351)
- Helen McShane (ORCID: https://orcid.org/0000-0002-2126-5142)
- Marcellus Korompis (ORCID: https://orcid.org/0000-0002-4457-1767)
- Alberta Ateere
- Shuailin Li (ORCID: https://orcid.org/0000-0002-7430-1717)
Institutions
- University of Oxford (GB)
- Jenner Institute (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1540359
- Citations
- 10
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 13.96
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- University of Oxford
- Lembaga Pengelola Dana Pendidikan
- Medical Research Council